Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection
The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.
You may also be interested in...
Ken Frazier says advocates need to ensure governments continue investing in global biosecurity.
Keeping Track: First COVID Vaccine BLA Kicks Off; Oncology Submissions From Hutchmed, Takeda And Shorla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The CDC and FDA recommended a pause on dosing of J&J's one-shot vaccine. Pfizer/BioNTech's vaccine showed signs of lower efficacy against the B.1.351 variant, but a prominent expert called the data "misleading." Gilead halted its Phase III study of Veklury in non-hospitalized, high-risk patients. And Rigel's Tavalisse may have a shot in the sickest COVID-19 patients despite the small size of a Phase II study.